10 results about "Acyl transferase" patented technology

The invention relates to a diacylglycerol acyltransferase capable of synthesizing triglyceride as well as a coding gene and application of the diacylglycerol acyltransferase, and belongs to the field of enzymology, the nucleotide sequence of the gene for coding the diacylglycerol acyltransferase is as shown in SEQ ID NO.1, and the amino acid sequence of the diacylglycerol acyltransferase is as shown in SEQ ID NO.2. The invention also provides a recombinant plasmid and a recombinant engineering bacterium containing the gene of the enzyme. Diglyceride and an acyl donor are used as substrates, and triglyceride is catalytically synthesized through an acyl transfer reaction by using the enzyme. The invention provides an efficient tool for realizing enzymatic biosynthesis and large-scale production of natural triglyceride.

The invention relates to a compound of formula (I): where A is an optionally substituted heteroaryl; useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The.invention also provides compositions comprising the compound for treating such disorders.

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and n are defined as in claim 1, which are ghrelin O-acyl transferase (GOAT) inhibitors for use in the treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

The invention provides recombinant yarrowia lipolytica for producing beta-elemene in a subcellular compartment and a construction method and application of the recombinant yarrowia lipolytica, and belongs to the field of bioengineering. The recombinant yarrowia lipolytica is prepared by taking yarrowia lipolytica as an original strain, performing localization expression on a germacene A synthase coding gene in a liposome through a liposome localization signal Oleosin, and knocking out a peroxisome biogenic factor 10 in a yarrowia lipolytica genome, so as to obtain the recombinant yarrowia lipolytica. And inserting into a 3-hydroxy-3-methylglutaryl CoA reductase expression cassette, a farnesyl pyrophosphate synthase expression cassette, an isopentenyl pyrophosphate isomerase expression cassette, a diacylglycerol acyltransferase expression cassette and a sterol acyltransferase expression cassette to obtain the recombinant expression vector. The recombinant yarrowia lipolytica disclosed by the invention can be used for efficiently producing beta-elemene.

This invention discloses a genetically engineered bacterium and its application in enhancing lactic acid production in *Escherichia coli*, belonging to the field of bioengineering. The genetically engineered bacterium of this invention uses *E. coli* as the starting strain and is obtained through genetic engineering operations. In this genetically engineered bacterium, the phosphoacetyltransferase-acetylkinase locus pta-ack and the alcohol dehydrogenase gene adhE are knocked out or deleted, while exogenous lactate dehydrogenase and exogenous monocarboxylic acid transporter genes are introduced and overexpressed. The modified genetically engineered bacterium, while retaining the advantages of *E. coli* such as easy culture and rapid growth rate, significantly improves the yield and conversion rate of lactic acid. Compared to the starting strain, the lactic acid concentration increases to 6 g / L with pta-ack knockout alone, and to 8 g / L with double knockout of pta-ack and adhE. Furthermore, the lactic acid concentration increases to approximately 20 g / L and 23 g / L with overexpression of exogenous lactate dehydrogenase and exogenous monocarboxylic acid transporter, respectively.

The invention belongs to the technical field of biological medicine and functional food, and discloses a fermentation composition based on signal peptide induction, which is prepared by the following steps: step 1, mixing astragalus membranaceus, lotus leaf, poria cocos and pericarpium citri reticulatae according to the mass ratio of (3-5): (2-4): (2-3): (1-2) to prepare a compound raw material; the fermentation composition is remarkable in effect and multi-target, the food intake can be reduced by reducing mRNA expression of hypothalamus neuropeptide Y and rat-related peptide and increasing the content of glucagon-like peptide-1, lipid metabolism can be regulated and controlled by improving mRNA expression of liver farnesoid X receptors, AMP-dependent protein kinase and carnitine palmitoyl transferase-1, and the food intake can be reduced by increasing the content of glucagon-like peptide-1. The abundance of intestinal bifidobacteria can be improved, and the expression of brown fat heat production related genes is promoted to balance intestinal flora; the safety of the composition is subjected to dual verification of animal and crowd tests, the weight and blood fat indexes of obese rats and obese crowds are remarkably improved, and the liver and kidney functions are not damaged.

The present invention provides a galactose-1-phosphate uridyl transferase mutant and its use in producing L-lysine. This galactose-1-phosphate uridyl transferase comprises the following A1) or A2): A1) a protein having the amino acid sequence set forth in SEQ ID NO: 2, and A2) a fusion protein in which a tag is linked to the N-terminus and / or C-terminus of A1). The present invention has discovered that the amount of L-lysine produced in cells can be increased by terminating or knocking out the gene encoding galactose-1-phosphate uridyl transferase in advance. L-lysine can be produced by mutating or knocking out the gene encoding galactose-1-phosphate uridyl acyl transferase in cells. The present invention has excellent applicability.

The present invention relates to compounds of general formula I,wherein the groups R1, R2 and n are defined herein, which are ghrelin O-acyl transferase (GOAT) inhibitors. The invention also relates to the use of compounds of formula (I) for treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

The present application relates to a kind of cancer immunotherapy polypeptide and application, disclose a kind of targeting PD-L1 lactylation modified treatment peptide, its preparation method and application in tumor immunotherapy drug, the treatment peptide amino acid sequence as shown in SEQ ID NO.3.The present application is based on the lactylation modification mechanism of PD-L1, according to the interaction region of lactoyltransferase HAT1 and PD-L1 design the treatment peptide, it can significantly reduce the interaction of HAT1 and PD-L1, reduce the lactylation level of PD-L1;The treatment peptide is combined with PD-1 antibody can further inhibit tumor growth, improve the immunotherapy effect of PD-1 antibody, suitable for the immunotherapy of ovarian cancer, lung cancer and other tumors.The present application provides new ideas and effective means for the immunological checkpoint therapy with PD-L1 as target, solves the technical problem of low objective response rate of existing PD-1 / PD-L1 inhibitor.